ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2221

Racial Differences in Cardiovascular Events and Adverse Pregnancy Outcomes Among Pregnant Individuals With Systemic Lupus Erythematosus

Rashmi Dhital1, Rebecca Baer2 and Christina Chambers3, 1Vanderbilt University Medical Center, Brentwood, TN, 2University of California San Diego, San Diego, CA, 3University of California, San Diego, La Jolla, CA

Meeting: ACR Convergence 2025

Keywords: Cardiovascular, Epidemiology, pregnancy, race/ethnicity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 28, 2025

Title: (2195–2226) Reproductive Issues in Rheumatic Disorders Posters

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Pregnant individuals with systemic lupus erythematosus (SLE) face an increased risk of cardiovascular events (CVEs) as well as adverse pregnancy outcomes (APOs). While racial differences in various SLE outcomes are known, the relationship between race/ethnicity, maternal CVEs, and APOs remains poorly understood.

Methods: Utilizing a California population-based birth cohort from 2005-2020, we identified pregnant individuals with SLE via International Classification of Diseases codes on maternal discharge records. The primary exposure was self-reported race/ethnicity, categorized as Asian, Hispanic, non-Hispanic Black, non-Hispanic White, and Other. Outcomes of interest included the occurrence of CVEs and APOs across racial groups. We also assessed APOs by race, separately for SLE pregnancies with and without CVEs. To assess how CVEs affect APO risk within each race, we estimated adjusted relative risks (aRRs) for APOs in SLE by CVE status for each race category. aRRs were adjusted using a propensity score created for race/ethnicity, incorporating age, payer, maternal education, clinical, and SLE-related variables.

Results: Among 8,422 live-born singletons from women with SLE, majority were from Hispanic (42.7%), followed by non-Hispanic White (27.7%) individuals. Private insurance was more common among Asian (78.7%) and non-Hispanic White (68.6%) women, while Hispanic and non-Hispanic Black patients more often had public insurance (51.4% and 52.2%, respectively). Non-Hispanic Black women had the highest prevalence of hypertensive disorders (Table 1). Compared to other racial groups, non-Hispanic Black women had the highest prevalence of CVEs during pregnancy (4.0% vs 1.6-2.0%), maternal APOs (24.6% vs 13.5-15.6%) and infant APOs (54.6% vs 34.6%-49.4%), including the highest infant death rate (1.8%) (Table 2).Stratified analysis by race/ethnicity and CVE status showed the highest occurrences of maternal and infant APOs in non-Hispanic Black women, regardless of CVE status (23.4% and 42.1% without CVEs; 51.6% and 83.9%, with CVEs, respectively). In non-Hispanic White women, maternal and infant APOs occurred in 13.4% and 27.7% without CVEs, and 25.6% and 58.1% of those with CVEs, respectively. (Table not shown).In the subanalysis, CVEs in SLE were associated with higher risks of most APOs across all groups. The aRR for maternal APOs was 3.1-fold in Asian patients, 2.5-fold in Hispanic patients, and 1.9-fold in both non-Hispanic Black and White patients. For infant APO, aRRs ranged from 1.4- 1.7-fold in SLE pregnancies with CVEs compared to those without, across all groups (Table 3).

Conclusion: CVEs in SLE were linked to higher APO risks. The relative impact of CVEs on maternal APOs was higher for Asian (aRR 3.1) and Hispanic (aRR 2.5) women than the 1.9-fold higher risk of maternal APO observed in non-Hispanic Black and White women with CVEs as compared to those without CVEs. However, non-Hispanic Black women consistently experienced the highest absolute burden of CVEs and maternal and infant APOs, including infant deaths. These findings underscore the importance of integrating cardiovascular disease risk and social determinants of health into the clinical care of pregnant patients with SLE.

Supporting image 1Table 1. Baseline sociodemographic characteristics and clinical comorbidities compared between racial groups in pregnant individuals with SLE, 2005 – 2020

Supporting image 2Table 2. Cardiovascular events (CVEs) and adverse pregnancy outcomes (APOs) compared between racial groups in pregnant individuals with SLE, 2005 – 2020

Supporting image 3Table 3. Risk of an APO among individuals with SLE with a CVE versus SLE without a CVE, stratified by race/ethnicity


Disclosures: R. Dhital: None; R. Baer: None; C. Chambers: Amgen, 5, AstraZeneca, 5, Bristol-Myers Squibb(BMS), 5, Genzyme Sanofi-Aventis, 5, Gerber Foundation, 5, Gilead, 5, GlaxoSmithKlein(GSK), 5, Hoffman La-Roche-Genentech, 5, Janssen, 5, Leo Pharma, 5, Novartis, 5, Pfizer, 5, Regeneron, 5, Sanofi, 5, Sun Pharma Global FZE, 5, Takeda Pharmaceutical Company Limited, 5, UCB Pharma, 5.

To cite this abstract in AMA style:

Dhital R, Baer R, Chambers C. Racial Differences in Cardiovascular Events and Adverse Pregnancy Outcomes Among Pregnant Individuals With Systemic Lupus Erythematosus [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/racial-differences-in-cardiovascular-events-and-adverse-pregnancy-outcomes-among-pregnant-individuals-with-systemic-lupus-erythematosus/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/racial-differences-in-cardiovascular-events-and-adverse-pregnancy-outcomes-among-pregnant-individuals-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology